How Pharma Can Fix Its Reputation and Its Business at the Same Time

The traditional business model of pharmaceutical companies based on research is in decline just as the reputation of these. How can they reconcile their business with their reputation? You will find the answer in this great article from Harvard Business Review!

"The business model of research-based pharmaceutical companies is under significant pressure. Their return on R&D investment has dropped to its lowest levels in decades, and their public reputation in the United States and abroad is worse than ever.

 

One antidote to these problems is to transform “access to medicine” from a relentless activist slogan to a fully-fledged business strategy. By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible. This strategy will tap potential growth in emerging markets, limit the risks of misconduct, and improve public trust in the industry.

It’s a fact that the current business model of pharma companies is not working efficiently. For each $1 billion spent on R&D, the number of new medicines approved has halved roughly every nine years since 1950. The estimated return on these (fewer) products has itself declined substantially since 2010, from 10.1% to 3.7%.”

 

To read more:

https://hbr.org/2017/02/how-pharma-can-fix-its-reputation-and-its-business-at-the-same-time

 

Share on Facebook
Share on Twitter
Please reload

New posts

6 Elevator Pitch Examples to Inspire Your Own

October 30, 2017

1/10
Please reload

Search by Tags
Please reload

Recent posts
Please reload

Follow us
  • LinkedIn Social Icon
  • Twitter Basic Square